COMP <GO>
USPH vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
U.S. Physical Therapy Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: USPH 5
— ABBV 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $86.57 (+1.47%) • MKT CAP: $1.29B
roic
11.50%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (USPH VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | USPH | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 19.20% | 70.20% | -51.00 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 11.50% | 29.00% | -17.50 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 16.3x | 33.3x | -17.00 | USPH | /valuation <GO> |
| Free Cash Flow Yield | 5.81% | 3.47% | +2.34 | USPH | /fcf-yield <GO> |
| Operating Margin | 11.10% | 24.60% | -13.50 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 5.10% | 6.90% | -1.80 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 16.30% | 8.60% | +7.70 | USPH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.12% | 2.27% | -0.15 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.94 | 5.33 | -2.39 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | USPH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.3 | 65.1 | -12.85 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.4x | 113.1x | -85.70 | USPH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.29B | $513.86B | -$512.57B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | USPH REV | ABBV REV | USPH GROSS % | ABBV GROSS % | USPH FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $781.0M | $61.16B | 19.2% | 70.2% | $75.1M | $17.82B |
| FY 2024 | $671.3M | $56.33B | 18.5% | 70.0% | $74.9M | $17.83B |
| FY 2023 | $604.8M | $54.32B | — | — | $82.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
USPH // BETA —
ABBV // BETA 1.15